WHO ICTRP trial
Phase 2 double blind study of cenerimod
JPRN-jRCT2011210019 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2011210019 |
|---|---|
| Public title | Phase 2 double blind study of cenerimod |
| Scientific title | A randomized, double-blind, parallel-group, multicenter, phase 2 study to investigate the safety and PD of cenerimod in Japanese subjects with moderate to severe systemic lupus erythematosus (SLE) |
| Primary sponsor | Yokoyama Yoshinari |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | Systemic lupus erythematosus |
| Interventions | Administration of two doses of cenerimod (2 and 4 mg) given orally once daily for 3 months in adult subjects with moderate to severe SLE concurrently receiving SLE background treatment |
| Registration date | Jun 30, 2021 |
| Target size | 16 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: